Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer
Keyword(s):
Phase 2
◽
2014 ◽
Vol 9
(7)
◽
pp. 1031-1035
◽